Control Of Nitrosamine Impurities In Human Drugs

Control of Nitrosamine Impurities in Human Drugs: What the FDA Actually Expects From You

It started with ranitidine. Then it was losartan. Consider this: then metformin. Which means one by one, common drugs started testing positive for nitrosamine impurities — compounds that, at high enough levels, are reasonably anticipated to cause cancer in humans. And suddenly, every drug manufacturer with a sartan, a diabetes med, or an antacid in their portfolio was scrambling.

If you're in pharma, you already know this story. But here's what most people don't* know: the regulatory expectations around nitrosamine control have evolved dramatically since 2018, and the bar keeps moving. In real terms, it's not enough to test your finished product anymore. You need to understand where* nitrosamines form, how they got there, and what you're going to do about it before the FDA shows up with a Form 483.

Let's break it down.

What Are Nitrosamine Impurities, Really?

Nitrosamines are a class of compounds that share a common structural feature: a nitroso group (N–N=O) attached to a secondary amine. Sounds like organic chemistry trivia, right? It's not. These molecules show up in everything from cured meats to tobacco smoke — and, under the wrong conditions, in your drug substance.

The concern isn't theoretical. Several nitrosamines, including N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), and N-nitrosodipropylamine (NDPA), are classified as probable human carcinogens based on long-term animal studies. The International Agency for Research on Cancer (IARC) has placed many of them in Group 2A or 2B.

In drug products, even trace amounts matter. Because of that, we're talking nanograms. The acceptable daily intake limits are extremely* low — often in the single-digit ng/day range, depending on the specific nitrosamine and the duration of treatment.

Why Nitrosamines End Up in Drugs

This is the part most companies underestimated at first. Everyone assumed nitrosamines were a problem only for sartans — drugs with a tetrazole ring that was vulnerable to nitrosation. Turns out, that's just the beginning.

Sources During API Manufacturing

Some nitrosamines are introduced through contaminated starting materials or reagents. Sodium nitrite, for example, is used legitimately in some synthetic pathways but can leave behind nitrosating agents. Solvents like DMF or DMAc, if contaminated with secondary amines, can also generate nitrosamines during processing. And then there's the issue of recovered solvents — if those aren't properly purified, they can carry amines into subsequent batches.

Sources During Formulation and Storage

This is where it gets sneaky. Still, the result? But even if your API is clean, certain excipients — particularly those with secondary or tertiary amines, like some grades of microcrystalline cellulose or magnesium stearate — can react with nitrosating agents under acidic or heated conditions. So nitrosamines form in the drug product over time*. A tablet that passes release testing might fail at six months on stability.

Sources From Packaging

There's also growing attention on nitrosamines that can migrate from packaging components. Certain rubber stoppers, adhesives, or print inks contain amine-based compounds that, under the right conditions, can contribute to the total nitrosamine burden in a drug product. It's not the most common source, but it's on the FDA's radar.

How the FDA Expects You to Control It

The FDA's guidance on nitrosamines has gone through several revisions, and the current expectation is essentially a three-part framework: assess, detect, and control.

Step 1: Conduct a Risk Assessment

Every manufacturer — whether you hold a US application or not, if you're supplying the US market — is expected to perform a thorough risk assessment for nitrosamine formation across your entire portfolio. This isn't a one-time exercise. It needs to be revisited when:

• You change a manufacturing process
• You change a starting material supplier
• You change formulation components
• New nitrosamine information becomes available (and it does, regularly)

The assessment should look at every step — from API synthesis through drug product manufacture, packaging, and storage — and identify where nitrosating agents and secondary amines could come into contact.

Step 2: Develop and Validate Sensitive Analytical Methods

You can't control what you can't measure. And measuring nitrosamines at regulatory-relevant levels is genuinely hard. Still, the limits are so low that standard HPLC methods often don't cut it. Most labs turn to LC-MS/MS or GC-MS/MS with specialized sample prep — sometimes solid-phase extraction, sometimes derivatization — to push detection limits down into the parts-per-billion range.

Method validation needs to address specificity, sensitivity, linearity, accuracy, and precision at the actual limit of quantification you'll be reporting against. And if you have multiple nitrosamines of concern, you'll likely need a method that screens for all of them simultaneously.

Step 3: Implement Controls and Change Specifications Where Needed

Once you know your risk, you need to do something about it. That might mean:

• Replacing a high-risk excipient with a lower-risk alternative
• Adding an antioxidant like ascorbic acid or alpha-tocopherol to the formulation
• Modifying the manufacturing process to eliminate nitrosating conditions
• Setting specification limits for individual or total nitrosamines in both the API and the drug product
• Tightening your supplier qualification and incoming material testing

The FDA has been pretty clear: they expect a control strategy, not just data. Showing that your product tests below the limit isn't enough if you can't explain why it stays below the limit over time.

Common Mistakes Companies Make With Nitrosamine Control

I've seen the same handful of missteps come up again and again.

Testing the finished product only. If you're only catching nitrosamines at the drug product stage, you're catching them too late. By then, your options are limited: reject the batch, recall the product, or — worst case — explain to regulators why you didn't have a preventive strategy.

Treating the risk assessment as a checkbox. Some companies perform a risk assessment on paper that ticks every box but doesn't actually engage with the chemistry. A real assessment considers the conditions* under which nitrosamines could form — pH, temperature, the presence of catalysts, the order of reagent addition — not just whether nitrosating agents are theoretically present.

Ignoring the drug product. The early recalls were mostly about API contamination. But the FDA has shifted its focus to drug product risk too, because that's where excipient-related and stability-related nitrosamines can sneak in. If your assessment only covers the API, you're exposed.

Underestimating the impact of packaging. As I mentioned earlier, this one's still flying under the radar for many companies. It's worth a closer look, especially for liquid and semi-solid dosage forms.

Waiting for the FDA to call. Don't. The agencies have signaled repeatedly that they expect proactive risk management. The companies that are responding well aren't the ones scrambling after a warning letter — they're the ones who built nitrosamine control into their quality systems three years ago.

For more on this topic, read our article on how many periods are in the periodic table or check out acs award for team innovation established.

What Actually Works in Practice

So what does a solid nitrosamine control program actually look like? In my experience, the companies doing this well tend to do a few things consistently.

First, they build a cross-functional team — not just QA, but also process chemistry, formulation, analytical, regulatory, and supply chain. Nitrosamine control doesn't live in a single department. It requires people who understand synthetic routes, people who understand excipient interactions, and people who understand regulatory expectations all talking to each other.

Second, they treat their risk assessment as a living document. It's reviewed at least annually, and it's updated whenever there's a process change, a new supplier, or new information from regulators or the literature.

Third, they invest in method development early. Waiting until you have a confirmed finding to start developing a sensitive analytical method is a recipe for delays. The companies that move fastest are the ones who already had LC-MS/MS capability in-house before they ever had a problem.

Fourth, they communicate with the FDA. If you identify a risk, don't bury it. The FDA has, in many cases, been more lenient with companies who come forward proactively than with those who get caught after the fact. The recommended AI limits vary by compound, and the agency has been willing to discuss risk-based approaches on a case-by-case basis.

If you take away one thing from this section, make it this.

Frequently Asked Questions

What is the acceptable daily intake for nitrosamines in drugs?

It depends on the specific nitrosamine. For NDMA, NDEA, NMDBR, NMPA, NDIPA, and NDBA, the FDA has set limits based on the carcinogenic potency categorization approach — typically ranging from about

It depends on the specific nitrosamine. For NDMA, NDEA, NMDBR, NMPA, NDIPA, and NDBA, the FDA has set limits based on the carcinogenic potency categorization approach — typically ranging from about 1 ng per kg body weight per day for the most potent compounds (equating to roughly 1–100 ng per day for a 70‑kg adult) down to 1 µg per day for those with lower potency. In practice, these values are expressed as the maximum allowable dose per day per batch of drug product, and sponsors must demonstrate that their product stays well below the applicable threshold.

Putting the limits into a working framework

1. Risk‑based acceptance criteria – Rather than treating the FDA‑published numbers as static ceilings, leading companies translate them into a “risk budget” for each drug substance and product. The budget is calculated using the daily dose of the medication, the nitrosamine’s potency category, and any additional mitigation (e.g., purification steps, analytical control limits). This budget becomes the target for all subsequent control activities.

2. Early‑stage analytical readiness – With the risk budget in hand, the analytical team can set a method detection limit (MDL) that is at least an order of magnitude lower than the highest acceptable level. For high‑potency nitrosamines, an MDL in the low‑ng range is common; for lower‑potency agents, a sub‑µg MDL may be sufficient. Having the method validated before any issue arises eliminates the need for emergency method development and the associated timeline extensions. Turns out it matters.

3. Supplier and excipient stewardship – Because many nitrosamine sources are linked to specific reagents or excipients, a reliable supplier‑qualification program is essential. Companies that require full impurity profiles from raw‑material vendors, and that audit those vendors regularly, dramatically reduce the chance of an unexpected nitrosamine burst. In practice, this means:

   • Requesting certificates of analysis that list not only the API impurity profile but also any known nitrosamine‑related impurities in excipients or solvents.
   • Conducting periodic “screen‑and‑verify” testing of incoming batches using a rapid, high‑sensitivity technique (e.g., LC‑MS/MS with a low‑volume sample preparation).
   • Maintaining a “red‑flag” list of high‑risk materials (e.g., certain amines, nitrite‑rich solvents, or metal catalysts) and ensuring that any change in source triggers a re‑evaluation of the risk assessment.

4. Process‑design safeguards – The most effective controls are built into the synthesis itself. Strategies that have proven successful include:

   • In‑process quenching of nitrosating agents (e.g., using ascorbic acid or other reducing agents) before they can react with secondary amines.
   • Solvent selection that minimizes nitrite formation; for example, preferring anhydrous conditions and avoiding prolonged storage of aqueous solutions that contain nitrite.
   • Catalyst control – employing catalysts that do not promote nitrosation (e.g., avoiding copper‑based systems in steps where secondary amines are present).

5. Continuous monitoring and trend analysis – Even after a product is approved, the nitrosamine risk can evolve. Companies that embed routine trend analysis into their manufacturing dashboards can spot subtle increases in impurity levels before they cross the acceptance threshold. Automated alerts based on control‑chart rules (e.g., Westgard criteria) keep the quality team proactive rather than reactive.

6. Regulatory dialogue – Transparent communication with the FDA (or other health authorities) is a differentiator. When a potential nitrosamine signal is identified, a timely, data‑rich submission that outlines:

   • The nature of the risk,
   • The mitigation steps already in place,
   • The revised risk budget, and
   • A clear plan for ongoing control, often results in a collaborative rather than punitive response. Historical examples show that sponsors who present a well‑structured risk‑management update are viewed favorably and may avoid more stringent post‑approval inspections.

The bottom line

A nitrosamine control program that truly protects patients and sustains market viability must be:

• Multidisciplinary – bringing together chemistry, formulation, analytical, regulatory, and supply‑chain expertise from day one.
• Dynamic – treating the risk assessment as a living document that evolves with process changes, new scientific information, or regulatory guidance.
• Analytically empowered – investing in sensitive, validated methods before a problem surfaces, thereby eliminating delay when a finding occurs.
• Proactively communicated – sharing risk information with regulators early, demonstrating a culture of responsibility that can soften regulatory repercussions.

By embedding these principles into the quality system, companies move from a reactive “wait‑for‑the‑FDA‑call” stance to an anticipatory, risk‑based approach that safeguards product integrity, protects patient health, and preserves commercial continuity. The cost of building these capabilities up front is far less than the financial, reputational, and clinical impact of a later‑stage nitrosamine incident.